153 228

Cited 26 times in

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

DC FieldValueLanguage
dc.contributor.author배미경-
dc.contributor.author이진구-
dc.contributor.author이창영-
dc.contributor.author정경영-
dc.contributor.author김대준-
dc.contributor.author박성용-
dc.date.accessioned2014-12-18T09:09:10Z-
dc.date.available2014-12-18T09:09:10Z-
dc.date.issued2013-
dc.identifier.issn1749-8090-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87631-
dc.description.abstractBACKGROUND: Although overall survival for non-small cell lung cancer (NSCLC) has increased, survival rate for pathologically staged T2aN0M0 stage IB NSCLC remains low. Adjuvant chemotherapy is not a standard treatment for stage IB NSCLC. Our purpose was to determine the efficacy of platinum-based adjuvant chemotherapy in stage IB NSCLC. METHODS: We retrospectively reviewed the medical records of 119 stage IB patients who underwent lobectomy and mediastinal lymph node dissection. Among these, 60 patients underwent platinum-based adjuvant chemotherapy (adjuvant group) and 59 did not receive chemotherapy (observation group). RESULTS: Participants had a mean age of 62.12 ± 11.51 years and 73 (61.3%) were male. The median follow-up period was 49.04 months. Mean age was higher in the observation group whereas patients in the adjuvant group had larger tumors, more dissected lymph nodes, and better performance status. The 5-year overall survival was 64.7% in the observation group and 88.2% in the adjuvant group (p = 0.010). The 5-year disease-free survival was 51.3% in the observation group and 74.0% in the adjuvant group (p = 0.011). In multivariate analysis, only platinum-based adjuvant chemotherapy was a risk factor for overall survival [hazard ratio (HR) = 0.428, p = 0.049] and disease-free survival (HR = 0.57, p = 0.043). In subset analysis, patients with a larger tumor (greater than 3.2 cm), moderate to poor differentiation, and good performance status (Eastern Cooperative Oncology Group, 0) benefitted from platinum-based adjuvant chemotherapy. CONCLUSIONS: Platinum-based adjuvant chemotherapy for surgically treated stage IB NSCLC might offer better survival than observation alone. A large-scale randomized clinical trial is needed to validate these findings.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJournal of Cardiothoracic Surgery-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHArea Under Curve-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/surgery-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDiagnostic Imaging-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/pathology*-
dc.subject.MESHLung Neoplasms/surgery-
dc.subject.MESHLymph Node Excision-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHPneumonectomy-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHVinblastine/administration & dosage-
dc.subject.MESHVinblastine/analogs & derivatives-
dc.titleEfficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery (흉부외과학)-
dc.contributor.googleauthorSeong Yong Park-
dc.contributor.googleauthorJin Gu Lee-
dc.contributor.googleauthorJieun Kim-
dc.contributor.googleauthorGo Eun Byun-
dc.contributor.googleauthorMi Kyung Bae-
dc.contributor.googleauthorChang Young Lee-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorKyung Young Chung-
dc.identifier.doi10.1186/1749-8090-8-151-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01792-
dc.contributor.localIdA03225-
dc.contributor.localIdA03245-
dc.contributor.localIdA03571-
dc.contributor.localIdA00368-
dc.contributor.localIdA01508-
dc.relation.journalcodeJ01290-
dc.identifier.pmid23759129-
dc.subject.keywordLung cancer surgery-
dc.subject.keywordAdjuvant therapy-
dc.subject.keywordStatistics-
dc.subject.keywordSurvival analysis-
dc.contributor.alternativeNameBae, Mi Kyung-
dc.contributor.alternativeNameLee, Jin Gu-
dc.contributor.alternativeNameLee, Chang Young-
dc.contributor.alternativeNameChung, Kyung Young-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNamePark, Seong Yong-
dc.contributor.affiliatedAuthorBae, Mi Kyung-
dc.contributor.affiliatedAuthorLee, Jin Gu-
dc.contributor.affiliatedAuthorLee, Chang Young-
dc.contributor.affiliatedAuthorChung, Kyung Young-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.contributor.affiliatedAuthorPark, Seong Yong-
dc.rights.accessRightsfree-
dc.citation.volume8-
dc.citation.number1-
dc.citation.startPage1-
dc.citation.endPage8-
dc.identifier.bibliographicCitationJournal of Cardiothoracic Surgery, Vol.8(1) : 1-8, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.